comparemela.com

Latest Breaking News On - Medimmune limited - Page 1 : comparemela.com

Aridis Provides Corporate Update

LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical.

Asher biotherapeuticsCraig gibbsVu truongMatt sheldonAridis pharmaceuticalsAridis pharmaceuticals incRedchip companies incCystic fibrosis foundationCompany phaseMedia communicationsMedimmune limitedExchange commissionVentilator acquired pneumoniaLicense agreementNasdaq ardsAridis pharmaceuticals

Aridis Provides Corporate Update

Aridis Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vu truongCraig gibbsAsher biotherapeuticsAridis pharmaceuticalsAridis pharmaceuticals incInvestor relationsdave gentryredchip companies incMatt sheldonredchip companies incCompany phaseMedia communicationsCystic fibrosis foundationExchange commissionMedimmune limitedVentilator acquired pneumoniaLicense agreementRelationsdave gentryredchip companies inc

Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT . | March 29, 2023

United statesLos gatosVu truongAridis pharmaceuticals incSecurities exchangeMedimmune limitedExchange actSecurities actSecurities exchange actMaterial definitiveAridis pharmaceuticalsLicense agreementUpfront cash paymentNc stock exchangePress releaseUrrent ards us0403341045

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007

Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of.

United statesUnited kingdomCity ofGarrya neilRichard masonChristopher sullivanChris brinzeyKate burdickUniversity college londonKings college londonAvalo therapeutics incApollo therapeutics groupCanale communicationsUniversity of cambridgeImperial college londonApollo therapeutics group limited

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

Transferred anti-IL 18 monoclonal antibody product to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2 PEAK. | August 4, 2022

United statesGarry neilChristopher sullivanChris brinzeyGroup study to evaluate the safetyAvalo therapeutics incDrug administrationApollo therapeutics group limitedProgram updatesApollo therapeuticsLeukocyte adhesion deficiency typeChief executive officerMedimmune limitedNasdaq capitalLoan agreementParallel group study

vimarsana © 2020. All Rights Reserved.